<DOC>
	<DOC>NCT01640873</DOC>
	<brief_summary>This study will assess the initial safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-8655, after single and multiple daily oral administrations to participants with Type 2 Diabetes (T2DM). The study will assess the reduction in fasting plasma glucose concentrations from baseline after multiple daily administrations of MK-8655.</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002 AM1)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Male or female of nonchild bearing potential Body Mass Index â‰¤40 kg/m^2 Diagnosis of Type 2 Diabetes (T2DM) and is either drug naive or is being treated with metformin only In good health except for T2DM Willing to follow a standard diet Nonsmoker and/or no use of nicotine or nicotinecontaining products for 6 months Mentally or legally incapacitated History of stroke, chronic seizures, or major neurological disorder History of clinically significant endocrine (except T2DM), gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases History of neoplastic or myeloproliferative diseases Has clinical unstable or rapidly progressing diabetic retinopathy, neuropathy, and/or frequent nausea, bloating or vomiting, severe gastroesophageal reflux or early satiety Has a history of Type 1 Diabetes and/or history of ketoacidosis Use of any lipidlowering therapies in the past 3 months Nonpermitted medication for a comorbid condition Excessive alcohol or caffeine use Participation in another investigational study within 4 weeks prior to this study A history of significant multiple and/or severe allergies or anaphylactic reactions Regular user of any illicit drugs or history of alcohol abuse within 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Type 2 Diabetes</keyword>
</DOC>